Our top pick for
Fortress Biotech, Inc is a biotechnology business based in the US. Fortress Biotech shares (FBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Fortress Biotech employs 93 staff and has a trailing 12-month revenue of around USD$43.3 million.
|52-week range||USD$1.04 - USD$4.78|
|50-day moving average||USD$3.9117|
|200-day moving average||USD$3.0151|
|Wall St. target price||USD$9.46|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.119|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$43.3 million|
|Gross profit TTM||USD$26.1 million|
|Return on assets TTM||-25.17%|
|Return on equity TTM||-106.89%|
|Market capitalisation||USD$240.9 million|
TTM: trailing 12 months
There are currently 2.2 million Fortress Biotech shares held short by investors – that's known as Fortress Biotech's "short interest". This figure is 6.9% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Fortress Biotech shares can be evaluated.
Fortress Biotech's "short interest ratio" (SIR) is the quantity of Fortress Biotech shares currently shorted divided by the average quantity of Fortress Biotech shares traded daily (recently around 1.6 million). Fortress Biotech's SIR currently stands at 1.34. In other words for every 100,000 Fortress Biotech shares traded daily on the market, roughly 1340 shares are currently held short.
However Fortress Biotech's short interest can also be evaluated against the total number of Fortress Biotech shares, or, against the total number of tradable Fortress Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fortress Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Fortress Biotech shares in existence, roughly 20 shares are currently held short) or 0.0331% of the tradable shares (for every 100,000 tradable Fortress Biotech shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fortress Biotech.
Find out more about how you can short Fortress Biotech stock.
We're not expecting Fortress Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Fortress Biotech's shares have ranged in value from as little as $1.04 up to $4.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fortress Biotech's is 2.2041. This would suggest that Fortress Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.